Hypertrophic cardiomyopathy (HCM) is characterized by enlargement of the ventricular muscle without dilation and is often associated with dominant pathogenic variants in cardiac sarcomeric protein genes. Here, we report a family with two infants diagnosed with infantile-onset HCM and mitral valve dysplasia that led to death before one year of age. Using exome sequencing, we discovered that one of the affected children had a homozygous frameshift variant in Myosin light chain 2 (MYL2:NM_000432.3:c.431_432delCT: p.Pro144Argfs*57;MYL2-fs), which alters the last 20 amino acids of the protein and is predicted to impact the C-terminal EF-hand (CEF) domain. The parents are unaffected heterozygous carriers of the variant and the variant is absent in control cohorts from gnomAD. The absence of the phenotype in carriers and infantile presentation of severe HCM is in contrast to HCM associated with dominant MYL2 variants. Immunohistochemical analysis of the ventricular muscle of the deceased patient with the MYL2fs variant showed marked reduction of MYL2 expression compared to an unaffected control. In vitro overexpression studies further indicate that the MYL2-fs variant is actively degraded. In contrast, an HCM-associated missense variant (MYL2:p.Gly162Arg) and three other MYL2 stopgain variants that lead to loss of the CEF domain are stably expressed. However, stopgain variants show impaired localization suggesting a functional role for the CEF domain. The degradation of the MYL2-fs can be rescued by inhibiting the cell's proteasome function supporting a post-translational effect of the variant. In vivo rescue experiments with a Drosophila MYL2homolog (Mlc2) knockdown model indicate that neither MYL2-fs nor MYL2:p.Gly162Arg
Introduction
Hypertrophic cardiomyopathy (HCM) is characterized by thickening of the ventricular walls in the absence of a cardiac or metabolic disorder that could account for the hypertrophy [1] [2] [3] [4] . It affects 1 in 200-500 individuals and has a strong genetic component [2, 3, [5] [6] [7] . It is a major cause of premature sudden cardiac death (SCD), with significant variability in the penetrance and onset of the disease [2, 5, 8] . The majority of HCM patients are asymptomatic, while some display exercise intolerance and progressive heart failure. The ventricular chamber in HCM patients is reduced or normal in size but displays a characteristic inability to properly relax during diastole leading to progressive loss of cardiac function [3, 4, [8] [9] [10] . The progressive disease is marked by a disorganized myocyte array in the heart, with significant fibrosis of ventricular walls [7, [11] [12] [13] .
Consistent with the myofibrillar disarray, about 60% of the cases of HCM have a genetic variant that is associated with the genes encoding the cardiac sarcomeric complex [4, 7, [14] [15] [16] . Of these sarcomeric genes, MYH7, MYBPC3, TNNI3, and TNNT2 account for a majority of the variants [13, [16] [17] [18] . Identification of novel variants in these genes and other HCM-associated genes has increased dramatically due to the advancement of high throughput genome and exome sequencing technologies [19] [20] [21] [22] [23] . However, the advancement of variant identification has also increased the number of potential sequence variants that could contribute to the disease in each individual, confounding the ability to assign pathogenicity to an individual variant [24] [25] [26] . While computational methods can predict the damaging effect of a variant and assist in prioritizing variants [27] [28] [29] [30] [31] [32] , the current consensus on the determination of pathogenicity is dependent on the identification of multiple patients showing similar symptoms and genetic variants with strong evidence of functional impact. Functional testing is therefore critical for disorders that are associated with rare variants in genes affecting a small subset of the patients [25, 33, 34] Variants in the gene MYL2 are associated with <5% of cases of HCM [5, 35] . MYL2 encodes the Myosin regulatory light chain expressed in the ventricular heart and slow-twitch skeletal muscles [36] . Even though MYL2 is considered as a candidate gene for HCM and a handful of pathogenic variants have been described in familial cases and population screens [23, [37] [38] [39] [40] [41] [42] , the lack of functional testing has prevented the designation of pathogenicity in many cases [43] .
Due to the variable penetrance and onset of the HCM phenotype, the pathogenicity of heterozygous MYL2 loss-of-function variants is hard to assess and have not been directly compared to pathogenic missense variants.
Human MYL2, together with the essential light chain (encoded by MYL3), stabilizes the 'lever arm' of the Myosin head [44] . Human MYL2 is a 18.8 kDa protein with three major domains: A single Ca 2+ -binding EF-Hand domain at the N-terminus, and two EF-Hand like domains in the C-terminus. The N-terminal region also carries a Serine residue (Ser15) which is phosphorylated by Myosin light chain kinase (MLCK) in response to Ca 2+ -mediated activation.
This phosphorylation, in turn, modulates the Ca 2+ -Tropomyosin-Troponin dependent activation of Myosin motors in skeletal and cardiac muscles [36] . Phosphorylation of MYL2 by MLCK shifts the equilibrium of the cyclic Myosin head binding to thin filament towards a bound state. This may be due to the increase in the number of cross-bridges between the myosin head and the actin filament and/or through the shift in the average position of the myosin head away from the thick filament and towards the thin filament [36, [45] [46] [47] [48] [49] . Correspondingly, variants in the N-terminal EF-hand domain of MYL2 that have defects in Ca 2+ binding or MLCK phosphorylation are associated with HCM [36, 47] . Several other missense variants that have been identified in both familial and sporadic cases of HCM have been tested in vitro and animal models [48, [50] [51] [52] [53] [54] [55] .
In mice and zebrafish, loss of the ventricular isoform of the regulatory light chain (Mlc-2v in mice and Myl7 in zebrafish) leads to embryonic lethality with defects in ventricular sarcomere assembly. This indicates the necessity of the regulatory light chain in heart development [56, 57] .
On the other hand, mice harboring Mlc-2v phosphorylation mutations or loss of MLCK develop to adulthood but die due to heart failure due to dilated cardiomyopathy (DCM) and cardiac hypertrophy with fibrosis [58] . This suggests that in mouse, Mlc-2v point mutations are not complete loss-of-function alleles but are hypomorphic alleles. In keeping with this observation, phosphorylation mutants in Drosophila regulatory light chain (Mlc2) display defect in skeletal muscle organization and flight performance defects in adults while nulls show recessive embryonic lethality [59] . It is worth noting that in mice, heterozygous loss of ventricular regulatory light chain (RLC) does not change the protein level or cardiac function, suggesting that compensatory mechanisms may exist that maintain the level of RLC in these mice [36] . Mice harboring an HCMassociated missense variant MYL2:p.E22K failed to display sarcomeric disarray or changes in cardiac function as measured by echocardiogram [60] , while a different mouse model harboring a DCM variant MYL2:p.D94A displays DCM-like phenotype similar to that observed in patients [53] .
Such discrepancy in mouse models carrying human variants suggests that disease pathogenesis may differ based on the specific MYL2 variant. Report of recessive mutations observed in a Dutch family, as well as an Italian patient with Type-I hypotrophy in skeletal muscle along with cardiomyopathy further adds to the variability in disease manifestation [61] . In these cases, MYL2 variants are thought to be loss-of-function variants, affecting individuals as homozygous recessive, or compound heterozygous variants [61] . Heterozygous carriers of the variant were reported to be asymptomatic mirroring observations in mouse models, where the heterozygous loss of Mlc-2v does not cause a functional defect [61] .
In this study, we report a novel recessive variant in MYL2 identified through exome sequencing in a family where multiple infants have died within one year of age and were diagnosed to have HCM and mitral valve dysplasia. The parents, who are heterozygous carriers of the variant, were found to be normal based on the echocardiographic evaluation. Using in vitro analysis we demonstrate that the variant is not stable, and using in vivo functional analysis we show that these variants are loss-of-function alleles. By comparing this variant to other HCM-associated variants we propose a role for the C-terminal EF-hand domain in determining the stability of the protein.
This will inform in the evaluation of new variants in MYL2 and provide tools to facilitate rapid screening of these variants.
Results

Family with multiple infantile-onset hypertrophic cardiomyopathy and premature death
We identified a family with consanguinity in which four children had died before one year of age ( Fig 1A) . All four children were born at full-term through a Caesarian section and showed no gross developmental defects ( Fig 1B) . All four showed a rapid decline in health and were treated for various periods in neonatal intensive care units. Two of them, including the proband, showed a marked increase in heart size while all four children displayed hepatomegaly and general hypotonia ( Fig 1B, Fig S1A) . Echocardiographic evaluation of the proband showed severe biatrial dilatation and biventricular hypertrophy ( Fig S1A) . The patient also displayed severe mitral valve regurgitation with abnormal thickening of the mitral valve leaflets and pulmonary arterial hypertension. The proband and the siblings died within the first year of life due to refractory cardiogenic shock and cardiorespiratory arrest. Post-mortem examination of the proband's heart confirmed severe biatrial dilatation, significant biventricular hypertrophy with small ventricular cavities and severe mitral valve dysplasia ( Fig 1C) . The father (37 years old) and the mother (27 years old) of the proband, who are consanguineously related ( Fig 1A) , were asymptomatic from a cardiac standpoint as evaluated by an echocardiogram. While the similarities in the symptoms between the siblings indicated an underlying genetic cause for the disorder, the absence of a family history of cardiac problems confounded a clear diagnosis. Due to the remarkably early onset of HCM in the proband, as well as mitral valve abnormalities, we decided to perform genomic analysis to identify potential disease-contributing variants.
Whole exome sequencing to identify variants and prioritization of variants for functional analysis
We performed exome sequencing on the proband, the mother and the father. Sequencing data were analyzed using our previously published pipeline, Churchill, for calling variants [62] .
Variants were prioritized using minor allele frequency (<0.001) and damaging effect prediction by five out of the seven algorithms to filter variants ( Fig S1B) [27] [28] [29] [30] [31] [32] . This approach resulted in the identification of one de novo heterozygous variant in Olfactory Receptor Family 7 Subfamily C Member 1 (OR7C1:NM_198944.1:c.335delA:p.Asn112fs) and a homozygous variant in Myosin light chain 2 (MYL2:NM_000432.3:c.431_432delCT:p.Pro144Argfs*57) ( Fig 1D) . OR7C1 encodes an olfactory receptor protein that is not expressed in the heart. Therefore, we focused on the MYL2 variant (MYL2-fs). We confirmed the presence of the homozygous variant in the proband and that the parents are heterozygous carriers using Sanger DNA sequencing of the genomic region ( Fig 1D) . The dinucleotide deletion in the last exon of MYL2 is predicted to cause a frameshift variant of the protein that affects the last 20 amino acids in the C-terminal EF-Hand domain.
Moreover, the variant extends the reading frame of MYL2 into the 3′ UTR, leading to the addition of 36 amino acids to the C-terminal end. This MYL2-fs variant was not found in control populations in gnomAD, supporting the possibility of its association with this rare disorder.
Myocyte disarray, fibrosis, and reduction in the expression of MYL2 in the proband's ventricular muscle
To test the consequence of the variant, we examined the histopathology of the myocardium in the proband's ventricular muscle. Consistent with HCM diagnosis, the patient's ventricular muscle displayed myocyte disarray and a substantial increase in fibrotic tissue as evidenced by the H&E and Masson's trichrome staining respectively (Fig 2A) . Next, we examined the expression level of MYL2 using immunohistochemistry. We observed a significant reduction in the MYL2 protein levels in the proband's ventricular muscle compared to an unaffected control sample. In contrast, the expression level of a different sarcomeric protein, cardiac troponin I (TNNI3), in the proband was similar to control ( Fig 2B) . Also, MYL2 mRNA could be detected in the proband's ventricle using RT-PCR ( Fig 2C) . This suggests that the frameshift variant adversely affects the levels of MYL2 protein in the proband.
In vitro functional testing of the stability of MYL2 variants
We hypothesized that the reduction in the levels of MYL2 in the proband's ventricular muscle is due to the instability of the protein product with frameshift mutation. To test this hypothesis, we compared the stability of the wildtype and frameshift variants overexpressed in rat cardiomyoblast cells (H9c2 cells) [63] . We generated an EGFP-tagged human MYL2 cDNA construct that also expresses mCherry, permitting simultaneous evaluation of mRNA stability and protein stability. Using this construct, we tested the stability of MYL2-frameshift variant along with three other loss-of-function, stopgain alleles and a missense allele mapping to the C-terminal EF-hand domain (MYL2:p.G162R) reported in ClinVar ( Fig 3A) . While it is likely that the stopgain mutations (not found in the last exon of MYL2) will be degraded through non-sense mediated decay (NMD) when expressed from the genomic loci, the cDNA overexpression analysis allowed us to examine the effect of loss of different domains of the MYL2 protein. Using immunoblot analysis, we observed that overexpression of MYL2-fs variant was significantly reduced compared to truncation variants and the missense variant ( Fig 3B, Fig S3B) . However, there was no significant difference in the mCherry signal between these constructs ( Fig 3B) . We noticed that truncated variants did not localize in a pattern similar to the wild type MYL2 protein, which showed strong localization along the cytoskeleton of the cells ( Fig 3C) . The fs variant, however, was not detected in H9c2 cells compared to the wildtype control. Once again, there was no significant difference in the production of mCherry from fs variant constructs, suggesting that the read-through into the 3′ UTR does not destabilize the mRNA ( Fig 3C) . This prompted us to examine the mode of degradation of the MYL2-fs variant. We examined if the MYL2-fs variant is degraded by the proteasome machinery by treating the cells with MG-132, a commonly used pharmacological inhibitor of the proteasome. Indeed, when the H9c2 cells were treated with MG-132 after transfection with the MYL2-frameshift construct, the GFP signal corresponding to MYL2-fs was recovered ( Fig 3D) . However, it is worth noting that the MYL2-frameshift variant appears to be aggregating and has a weak affinity towards the cytoskeleton ( Fig 3D) . The binding of the MYL2-fs to myosin head may be affected as the modified residues are found close to the lever arm ( Fig S3A) . The aggregation suggests that the instability of the MYL2-fs variant might be due to misfolding or changes in the biochemical properties of the protein. Together, the in vitro experiments indicate that the MYL2-fs variant is not stable, and the loss of stability is due to proteasome-mediated degradation of the translated product and not due to changes in mRNA stability.
In vivo functional analysis using a Drosophila model of Myosin light chain knockdown in the dorsal tube
To test if any residual expression of the MYL2-fs variant could support myosin light chain function, we examined the ability of human wildtype MYL2 and variants to rescue the loss of Drosophila myosin light chain (Mlc2; Fig S4) expressed in the heart. We used Drosophila Hand-GAL4 driver to knock down the expression of Drosophila Mlc2 using transgenic RNAi lines ( Fig   4A) . This led to a significant loss in developmental viability, as measured by percent of observed adult survivors compared to the expected Mendelian frequency of the knockdown genotype ( Fig   4C) . In the knockdown background, using the same Hand-Gal4 driver, we overexpressed the human MYL2 cDNA or the variant carrying cDNAs to test the ability of the human MYL2 to functionally substitute fly Mlc2 ( Fig 4A) . We observed that the developmental lethality caused by cardiac knockdown of Mlc2 was partially rescued by the wildtype human MYL2 overexpression, while the overexpression of the frameshift variant identified in our proband or the MYL2-G162R missense variant failed to rescue the phenotype. To examine the specific effect of the knockdown and the variant overexpression in the heart, we focused on the cardiac function in the third instar larvae during the fly development. We used a membranous mCherry reporter (CD8::mCherry) to track the rhythmic contraction of the Drosophila heart between the posterior denticle belts (A7-A8) ( Fig 4B, Movie S1 ). Using this reporter driven by the Hand-GAL4, we measured fractional shortening of the heart and compared it between different genotypes ( Fig 4D, Movie S1-S5). We observed that loss of Mlc2 due to RNAi-mediated knockdown lead to a decrease in fractional shortening, which was again partially rescued by the wildtype human MYL2 cDNA overexpression. As seen with the developmental lethality, there was no rescue observed with the MYL2-fs or the MYL2-G162R variant in terms of fractional shortening (Fig 4 D , Movie S1-S5).
Partial rescue in both experiments can be attributed to sequence differences between the human and Drosophila homologs. Drosophila Mlc2 N-terminal region has additional sequences that have been shown to be needed for Mlc2 function [64] . Nevertheless, the in vivo analyses suggest that the frameshift variant and missense variant are functionally different from the wildtype human MYL2, and therefore will not support adequate cardiac function.
Discussion
Using next-generation exome sequencing methodology and our variant prioritization pipeline, we have identified in the gene MYL2, a rare and novel frameshift variant in a family with multiple infant deaths and early onset HCM. Consistent with this diagnosis, we found that the patient's ventricular myocardium shows a marked increase in fibrosis and myocyte disarray. The frameshift variant leads to a significant reduction in MYL2 in the ventricular myocardium. This variant does not destabilize the mRNA, as we could detect the transcript in the patient's ventricle as well as through the observation of mCherry reporter in the in vitro stability assay. The in vivo functional testing further demonstrated that any residual MYL2-fs variant present will not be able to adequately support cardiac function. The in vitro and in vivo tools generated in this study will permit rapid analysis of functional differences in variants of unknown significance in MYL2.
These functional testing results shed light on the molecular pathology of the MYL2-fs variant and recent reports of other recessive MYL2 variants leading to early-onset cardiomyopathy [61, 65] . The instability of the MYL2-fs variant suggests that any negative effects of MYL2-fs variant on the myosin function is not likely to be dominant. This conclusion is also supported by several loss-of-function variants reported in gnomAD, rendering the probable likelihood of intolerance for MYL2 to be zero [66] . This brings to the fore two aspects of MYL2 loss-of-function variants: 1) Loss-of-function variants may not contribute to HCM due to haploinsufficiency. 2)
There is a strong need to test individual variants to understand their mode of pathogenicity in order to develop a personalized therapeutics.
The development of the ventricular myocardium in the absence of MYL2 might be supported by the increase in the atrial light chain MYL7 expressed in the embryonic ventricle, as observed in the mouse models [56] . Whether such a response exists in dominant MYL2-variant associated myopathies remains to be investigated. This is important due to the observation that missense variants display reduced capacity to support myosin function in vitro [67] . However, the missense variants can still impart a negative effect on myosin function by affecting myosin contractility [48] . This may not be in the case in the stop-gain mutants that are likely to be degraded through NMD or frameshift variants that result in destabilized protein. The observation that lossof-function alleles display recessive inheritance while missense variants display dominant inheritance in HCM is supported by animal model analyses [56, 57] and is similar to genetic analysis of other sarcomeric genes [68] . However, the possibility exists that other variants in the patient could modulate the instability of the MYL2-fs variant, such as reduced proteasome function, that could easily stabilize the protein. Therefore, there is a need to identify modifiers and detect variants in these genes in future patients with MYL2 loss-of-function variants to determine the risk of HCM inheritance. Unlike the missense variants, where allele-specific silencing approach may provide a viable solution [69] , the treatment and management of recessive form of HCM will require an in utero diagnosis of the disorder and may involve gene therapy using a functional copy of MYL2. While this may not be immediately feasible, the diagnosis and genetic counseling of carriers need to be considered. 
Materials and Methods
Patient recruitment and DNA isolation:
Variant identification, prioritization, and confirmation:
The primary and secondary variant analysis was performed as described in our previous studies. The analysis of the sequencing data was conducted using the Churchill pipeline [62] , in which the data was aligned to GRCh37 using BWA mem, deduplicated using samblaster, and variants were jointly called across all samples using GATK's HaplotypeCaller. SnpEff, a software tool to annotate genetic variation, was used along with custom in-house scripts to provide mutation and gene information, protein functional predictions and population allele frequencies. Common variation occurring at >0.1% minor allele frequency in the population was excluded. Variants outside of coding regions (defined as >4 base pairs from an exon splice site) and exonic variants coding for synonymous single nucleotide polymorphisms were also dropped. In silico analysis was performed using algorithms to predict the pathogenicity of identified sequence variants. The following prediction software was used to analyze the rare variants in candidate CHD genes identified through WES: SIFT, GERP++, Polyphen2 Complex, Polyphen2 Mendelian, MetaSVM, MetaLR, and CADD [27] [28] [29] [30] [31] [32] . Variants were further filtered based on the expression of the impacted human gene in the developing heart using publicly available single-cell data [70] . MYL2 genomic region flanking the identified variant was amplified using MYL2.gen.For and MYL2.gen.Rev primers and the presence of the variant was confirmed using Sanger sequencing method.
Total RNA isolation from patient ventricle and RT-PCR: Four 7 micron sections of the left ventricle were used to isolate total RNA using the Quick-RNA TM FFPE kit (Zymo Research). 1 µg of total RNA was used to generate cDNAs using the SuperScript™ VILO™ cDNA Synthesis Kit. MYL2-IRES-mCherry or pUASt-MYL2-attB as the template and using the following primers and Agilent Quickchange II kit [71] . Sequences are provided in Table S1 . Drosophila transgenesis and crossing schemes: UAS-MYL2-attB constructs (300 ng/uL) were injected into 'Dm integrase with landing site VK37' stock to generate overexpression transgenic stocks using previously described methods with small modifications. F0 injection-survivors were crossed to yw animals and transgenic progeny from this cross (F1) were identified using red eye color. Stocks were generated using standard Drosophila mating schemes to generate UAS-MYL2 (wt or variant)/Cyo P{sqmCh}2; Mlc2 RNAi /TM3, Sb, P{sqmCh}3 stocks. These were crossed to UAS-CD8::mCherry/Cyo; GMR88D05-Hand GAL4/TM6, Ubx-LacZ animals and raised at 29 ℃ to maximize the effect of GAL4 mediated transcription. For developmental lethality, emerging adults irrespective of sex were used to determine percent adult survivors and compared to control crosses where Luciferease RNAi was overexpressed using Hand-GAL4. For cardiac function analysis, larvae of the desired genotype were identified using mCherry signal in the heart and the absence of muscle mCherry signal from the balancer chromosome.
Fluorescent reporter based fly cardiogram:
Crawling-third instar larvae were collected for each genotype and immobilized on a double-sided tape on a glass slide with the dorsal side of the larvae towards the camera. Videos were collected using an Olympus BX51 microscope with a DP71 camera. Each larva was imaged two times for 15 seconds each with 15 seconds gap. Kymographs of the videos were created, and systolic-diastolic widths of the heart tube were measured using ImageJ across 10 different contractions and averaged between the two videos for each animal.
Fractional-shortening was calculated as described in previous studies using the formula: % fractional shortening = (Avg. D -Avg. S) / (Avg. D) *100 where 'D' is the diastolic width and 'S' is the systolic width [72] .
Western blot: Immunoblots were performed using standard protocols prescribed for LI-COR biosciences method of detection using infra-red dye conjugated secondary antibodies. The following antibodies were used: Chicken anti-GFP (1:1000; Abcam: ab13970), Rabbit anti-mCherry (1:1000; Abcam: ab167453) and Rabbit anti-actin (1:1000; Abcam: ab1801).
Histology, Immunohistochemistry, and Immunofluorescence: Formalin-fixed and paraffinembedded ventricular myocardium of the deceased proband from the Department of Embryo-Fetopathology of Tunis and control heart from an unaffected donor of comparable age obtained from the Biospecimen repository at Nationwide Children's Hospital were sectioned and processed using standard methods. Hematoxylin and Eosin Staining [73] and Masson's trichrome staining [74] were used to study the histology of the samples. For immunohistochemistry following antibodies were used: Rabbit Anti-Myosin light chain 2 antibodies (1:500, Abcam: ab48003), Rabbit anti cardiac troponin I (TNNI3) (1:500, Abcam ab47003). For immunofluorescence, cells were fixed using 4% paraformaldehyde and processed for immunofluorescence using standard protocols. The following antibodies were used: Chicken anti-GFP (1:500; Abcam: ab13970) and
Rabbit anti-mCherry (1:500; Abcam: ab167453). Drosophila larvae were dissected and stained with Pericardin antibody (1:100, Developmental Studies Hybridoma Bank: EC11) as described previously. 
